bluebird bio - BLUE Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued twelve-month price targets for bluebird bio's stock. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 62.0% from the stock's current price.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.

bluebird bio's stock was trading at $6.92 at the beginning of the year. Since then, BLUE stock has decreased by 37.6% and is now trading at $4.32.
View the best growth stocks for 2023 here.

bluebird bio saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 20,510,000 shares, an increase of 12.2% from the February 28th total of 18,280,000 shares. Based on an average daily volume of 3,780,000 shares, the short-interest ratio is presently 5.4 days.
View bluebird bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our BLUE earnings forecast.

bluebird bio, Inc. (NASDAQ:BLUE) released its quarterly earnings data on Friday, November, 5th. The biotechnology company reported ($3.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.65) by $0.51. The biotechnology company earned $22.70 million during the quarter, compared to analysts' expectations of $39.07 million. bluebird bio had a negative trailing twelve-month return on equity of 173.58% and a negative net margin of 8,828.28%. bluebird bio's quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the business earned ($2.94) EPS.

ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Products ETF (BBP), Invesco DWA Healthcare Momentum ETF (PTH), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Global X Genomics & Biotechnology ETF (GNOM), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Invesco DWA SmallCap Momentum ETF (DWAS).

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (5.59%), Dimensional Fund Advisors LP (2.44%), Credit Suisse AG (2.00%), Geode Capital Management LLC (1.97%), JPMorgan Chase & Co. (1.56%) and Point72 Asset Management L.P. (1.46%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends.

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLUE stock can currently be purchased for approximately $4.32.

bluebird bio (NASDAQ:BLUE) has a market capitalization of $358.21 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($6.10) on an earnings per share basis.

The company employs 518 workers across the globe.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.